Breast

RAINN Welcomes HHS Action on Non-Consensual Pelvic Exams in America’s Teaching Hospitals

Retrieved on: 
Monday, April 1, 2024
RAINN, Patient, Public policy, Letter, Hospital, Light, HHS, Policy, Breast, Legislation, Nursing

“This letter from HHS is a critical leap forward in protecting patients and medical residents,” said Scott Berkowitz, president and founder of RAINN.

Key Points: 
  • “This letter from HHS is a critical leap forward in protecting patients and medical residents,” said Scott Berkowitz, president and founder of RAINN.
  • “Non-consensual sensitive exams are a shocking problem with a very simple solution: hospitals need to ask patients for consent, clearly and explicitly.
  • “Without consent, sensitive exams are a glaring violation of an anesthetized patient’s autonomy, whose body is being used for teaching purposes, without consent, in a vulnerable hospital setting,” said Stefan Turkheimer, vice president for public policy at RAINN.
  • “Requiring those in the medical profession to respect and obtain consent in all circumstances is a commitment to trauma-informed care and reinforces the importance of treating patients in a vulnerable setting with respect and dignity.”

Don’t Drop the Ball! The Urology Care Foundation Urges Men to Check Themselves for Testicular Cancer Awareness Month

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, American Urological Association, Breast, Risk, Testicular cancer, GCNIS, Medical college, Groin, Ache, Cancer, Epididymis, Scrotum, Male, Testicle, Thumb, Pain, AUA, Swelling, Courage, Birth control

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.

Key Points: 
  • BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.
  • Testicular cancer is one of the less common cancers in men, with only 1 out of every 250 men getting diagnosed during their lifetime.
  • The best way to increase the chances we can cure someone of testicular cancer is to catch it early.
  • Prostate exams, scrotal exams, penis stuff, all of it,” said C. Freeman McCluskey, MD, testicular cancer survivor and urology resident at the Medical College of Georgia.

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Fulvestrant, NMPA, AstraZeneca, Disease, Progression-free survival, CDX, Boehringer Ingelheim, Patient, Webcast, NGS, Hospital, Breast, Breakthrough, Safety, HR, Depreciation, ID, Precision, Food, Marketing, FDA, Cryptocurrency

Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.

Key Points: 
  • Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.
  • Total value of new contracts entered into during 2023 amounted to RMB310 million, representing a 24% increase from 2022.
  • Revenues were RMB121.1 million (US$17.1 million) for the three months ended December 31, 2023, representing a 14.9% decrease from RMB142.2 million for the same period in 2022.
  • Burning Rock will host a conference call to discuss the fourth quarter and full year 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on March 29, 2024.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, Consultant, Administration, Patient, Breast, Prostate, Insurance, IND, Data collection, Investment, Interim, Therapy, Research and development, FDA, NK, Pharmaceutical industry

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $1.81 million compared to $2.94 million for the same quarter in 2022.
  • Other income net of other expenses, for the fourth quarter ended December 31, 2023 was $0.21 million compared to $0.19 million for the same quarter ended December 31, 2022.
  • Net Loss: The Company reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023 compared to a loss of $5.58 million for the same quarter in 2022.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers

Retrieved on: 
Monday, April 8, 2024
FDA, Pharmaceutical, Health, Oncology, Acute lymphoblastic leukemia, Growth, Disease, Caregiver, New Drug Application, Patient, Nelarabine, NDA, Breast, Leukemia, Agency, Cancer, T-cell leukemia, Adenocarcinoma, Ovary, Food, Pharmaceutical industry

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.

Key Points: 
  • Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers.
  • The Agency assigned a Prescription Drug User Fee Act (“PDUFA”) action date of November 30, 2024.
  • “With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of U.S. patients diagnosed with leukemia and other cancers who do not currently have the option of an oral liquid,” said Sharon Cunningham, Chief Executive Officer and Co-Founder of Shorla Oncology.
  • The company recently raised $35 million in Series B funding that has allowed Shorla to accelerate the growth of its oncology portfolio.

Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Health, Oncology, AKT1, Mutation, Patient, Breast, Cancer, AACR, Hyperglycemia, PDX, Therapy, Pharmaceutical industry

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers.
  • ALTA-2618 is an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K.
  • AKT1 E17K is a clinically validated oncogene that drives cancers, including breast, endometrial, and prostate cancers.
  • “We’re excited to present data at AACR featuring Alterome’s lead program, ALTA-2618, the first AKT1 E17K-selective inhibitor.

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Science, Research, Oncology, Esophagus, Sensitivity, Prostate cancer, Survival rate, Patient, Lung, Exact sciences, Breast, Death, MD, Abstract, AACR, Cancer, Pancreas, Stomach, Liver, Ovary, Medical imaging

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

Key Points: 
  • Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.
  • These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening.
  • ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population.
  • Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types

Retrieved on: 
Monday, April 8, 2024
General Health, Pharmaceutical, Oncology, Data Management, Biometrics, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Biotechnology, Health, HER2, Database, Prevalence, Pfizer, Intelligence, Patient, Neoplasm, NGS, ERBB2, Research, RNA, Breast, Messenger, Medicine, AACR, Research fellow, Vaccine

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.
  • These findings may open up potential therapeutic routes for HER2-directed antibody-drug conjugates in several tumor types.
  • In 2022, Seagen (acquired by Pfizer in December 2023) engaged Tempus to investigate cohorts of patients with HER2 RNA expression.
  • As part of the collaboration, Tempus’ computational and real-world evidence teams helped provide insights on the prevalence of HER2 expression in select solid tumors.